Type
. Prevention of leprosy using rifampicin as chemoprophylaxis. The American journal of tropical medicine and hygiene [Internet]. 2005;72(4):443-8. Available from: https://kit2018.wpenginepowered.com/wp-content/uploads/2020/09/prevention.pdf
Type
. Disease in Africa: a medical perspective from the 1950s. Vesalius : acta internationales historiae medicinae. 2004;10(2):67-73.
Type
. [Correlation between dose/plasma concentration and assessment of hepatic and renal changes in Wistar rats treated with the ROM scheme]. Revista da Sociedade Brasileira de Medicina Tropical. 2005;38(2):167-72.
Type
. Misidentification of Mycobacterium leprae as Mycobacterium intracellulare by the COBAS AMPLICOR M. intracellulare test. Journal of clinical microbiology [Internet]. 2005;43(4):1928-9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1081340/pdf/1425-04.pdf
Type
. [Clofazimine. Current status of therapy with clofazimine (Lampren) for leprosy, erythema leprosum , and other dermatoses after donation of the medicine to the WHO by Novartis]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2005;56(5):478-9.
Type
. Leprosy: too complex a disease for a simple elimination paradigm. Bulletin of the World Health Organization [Internet]. 2005;83(3):230-5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2624210/pdf/15798849.pdf
Type
. Leprosy masquerading as lupus. Journal of the American Academy of Dermatology. 2005;52(4):702-3.
Type
. Microscopic leprosy skin lesions in primary neuritic leprosy. Journal of the American Academy of Dermatology. 2005;52(4):648-52.
Type
. [Social rehabilitation experiences of people with a history of Hansen's disease: interviews of readmitted residents in a sanatorium]. [Nihon koshu eisei zasshi] Japanese journal of public health. 2005;52(2):146-57.
Type
. [Detection of antibodies to M. leprae in saliva of lepric patients]. Klinicheskaia laboratornaia diagnostika. 2005;(1):52-4.